Ok, preface done, my hunch as to why people think Somas are weak from here or from there is because of how rapidly and intensely tolerance forms. I would guess that tolerance can triple within 10 days of consistent use, as when I begin using Soma 2.5g is the point where I get the classic Soma shakes, however after dose escalating for 10 days I can eat 6-7 full grams in a day without any issue.
Glad you're heading in the right direction after that journey and surgeries!
Agree that tolerance can be a factor, but I've experienced the same variation when using it recreationally for a year every 3 days or so while still not getting any reduction in effects generally week to week.
personally my guess is that peak blood plasma level is a key element, improving how quickly you get as much carisoprodol into your liver as possible so it can be metabolised into Meprobamate helps, as does hydration levels.
For a while I tried breaking up strips of Soma and mixing them up to create a blend from many pills to see if it was a hot spot issue, but that didn't seem to make any difference for me. it's only since taking them subligually have I got more stability, now I can notice when tolerance builds as well, every 3-4 days seems like that maximum without tolerance changes for me.
Also 1 thing we never talk about generally, there is a big difference in gender and race here as well to take into account - I think this might contribute to why you get mixed views on Soma with some people saying it doesn't work for them. Everyone is different as well so the ranges here might be much wider than it seems.
"
Absorption
The pharmacokinetics of carisoprodol was determined in a small in vivo biostudy of 5
men and 5 women. When the dose was normalized to 350 mg, the mean peak plasma
concentration (Cmax) achieved was 2.29 ± 0.68 ug/mL. Women tended to reach peak
plasma concentrations earlier than men (1.45 vs. 2.5 hours) and had a faster apparent oral
clearance (0.772 vs. 0.38 L/hour/kg). The clinical significance of these findings is
unknown and they may in part be due to the small number of subjects present in the trial.
Metabolism
Carisoprodol is metabolized in the liver via cytochrome P450 enzyme, CYP2C19. This
enzyme exhibits genetic polymorphism. For example, 15-20% of Asian populations may
be expected to be poor metabolizers. For Caucasians and Blacks, the prevalence of poor
metabolizers is 3-5%. Following a single 350 mg dose of carisoprodol, the
corresponding normalized peak concentration of meprobamate, which is a metabolite of
carisoprodol, was 2.08 ± 0.48 ug/mL. These levels are approximately ¼ of those seen
following a single 400 mg dose of meprobamate."